Dalteparin Versus Unfractionated Heparin In Patients With Acute Coronary Syndrome

• Status: Terminated
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To compare efficacy and safety of dalteparin compared to unfractionated heparin in patients of non ST elevation acute coronary syndromes who are planned to undergo coronary interventions (angioplasty or bypass surgery)

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Calcium heparin; Dalteparin; Heparin; Heparin, Low-Molecular-Weight; Tinzaparin

Criteria

Inclusion Criteria:

• Patients more than 18 years

• Ischemic pain of more than 10 minutes within 24 hours before enrollment

• At least two of the following three risk factors : Age more than 60 years ( or more than 50 in case of diabetics), Raised cardiac enzyme levels, abnormal ECG findings

Exclusion Criteria:

• Contraindications to use of anticoagulants

• Active bleeding or abnormal coagulation tests

• Ischemic stroke within last 6 months or hemorrhagic stroke

• Lumbar or spinal puncture within last 48 hours

• S creatinine levels more than 2